Skip to main content
OCS
NASDAQ Life Sciences

Oculis Q3 Loss Widens to CHF 18.2M as Expenses Climb; Cash Runs Into 2H 2029

Tom Rudovsky · Reported by Reuters
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$7.893
Mkt Cap
$471.016M
52W Low
$7.11
52W High
$34.475
52W Position info
11% above low
Off High info
77% below high
Rel. Volume info
2.1× avg
Market data snapshot near publication time

OCS is trading near its 52-week low of $7.11 (11% above the low) on elevated volume (2.1× avg).

Summary

Oculis posted a Q3 net loss of CHF 18.24 million, wider than the CHF 9.97 million loss reported for Q2, as operating expenses rose to CHF 23.65 million on higher headcount costs and non-recurring corporate initiatives. The company ended the quarter with $252 million in cash and equivalents and says that funds operations into the second half of 2029. Pipeline progress is the offset: patient randomization is complete in the Licaminlimab PREDICT-1 trial, with topline results expected around year-end 2026, and Privosegtor PIONEER-1 enrollment continues, with IND clearance for acute MS relapse trials anticipated in Q4 2026. The wider loss is a modest negative, but the runway and near-term readout are what matter for a company this size. The 6-K filed at 21:15 ET also raised the ATM ceiling from $100 million to $125 million, adding potential dilution overhang.

At the time of this announcement, OCS was trading at $7.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $471M. The 52-week trading range was $7.11 to $34.48. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

OCS - Latest Insights

OCS
Nov 16, 2026, 2:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $7.64
Real-time Price: $7.06 info
Change: -$0.580 (-8%) info
Market Cap: $435.828M info
OCS
Nov 03, 2026, 4:15 PM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $7.89
Real-time Price: $7.06 info
Change: -$0.833 (-11%) info
Market Cap: $435.828M info
OCS
Aug 10, 2026, 8:00 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $12.98
Real-time Price: $7.06 info
Change: -$5.92 (-46%) info
Market Cap: $435.828M info
OCS
Aug 10, 2026, 3:01 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $12.68
Real-time Price: $7.06 info
Change: -$5.62 (-44%) info
Market Cap: $435.828M info
OCS
Aug 06, 2026, 4:32 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $12.38
Real-time Price: $7.06 info
Change: -$5.32 (-43%) info
Market Cap: $435.828M info